{
  "abstract": "Following several randomised controlled trials (RCTs), therapeutic hypothermia (TH) has become the standard treatment for neonates with moderate to severe hypoxic-ischaemic encephalopathy (HIE) due to perinatal asphyxia.1 The trials were similar in terms of intervention and outcomes, but there were some differences in inclusion criteria. This laid the groundwork for hypothermia to be introduced into clinical practice with some inconsistencies. In fact, the eligibility criteria for TH remain highly variable between European countries, and this is also reflected in differences in national guidelines.2 Ideally, TH should be applied uniformly to patients with the same eligibility criteria, as represented by clinical or biological signs of perinatal asphyxia and/or moderate-to-severe encephalopathy as well as abnormal EEG or amplitude-integrated EEG (aEEG) findings. This approach was used, for instance, in the TOtal Body hYpothermia (TOBY) trial and was shown to improve the neurological outcome of survivors with HIE.3",
  "authors": [
    {
      "affiliations": [
        "Division of Paediatrics, AP-HP Université Paris Saclay, Le Kremlin-Bicêtre, Île-de-France, France",
        "INSERM U-999, Paris-Saclay University, Gif-sur-Yvette, France"
      ],
      "name": "Daniele De Luca"
    },
    {
      "affiliations": [
        "Department of Woman, Infant and Public Health, Catholic University of Sacred Heart, Rome, Italy"
      ],
      "name": "Tullio Ghi"
    }
  ],
  "title": "Variability in the use of therapeutic hypothermia in neonates across Europe",
  "uid": "bc7f0ebd-4265-51e4-ad8c-984a3beb9da0"
}